Osimertinib-chemotherapy extends PFS for EGFR-, TP53-mutant NSCLC

COPENHAGEN, Denmark — Adding chemotherapy to first-line osimertinib significantly improved survival for patients with EGFR-mutated advanced non-small cell lung cancer who also have TP53 mutations.
Findings from the randomized phase 3 TOP study, presented at European Lung Cancer Congress, showed adults treated with combination therapy had a 56% improvement in PFS compared with those who received osimertinib (Tagrisso, AstraZeneca) monotherapy.
OS trends significantly favored the combination arm, too, though the regimen did substantially increase toxicities.
“These findings provide key evidence to

Treating disordered eating in patients with obesity

SAN DIEGO — It is important to recognize various disordered eating behaviors among pediatric patients with obesity, according to speakers at the Obesity Medicine Association’s annual conference.
Valerie M. O’Hara, DO, FAAP, FOMA, DABOM, a pediatric obesity medicine physician at Knownwell, and Eileen A. Chaves, PhD, MSc, a pediatric psychologist at Nationwide Children’s Hospital’s Center for Healthy Weight and Nutrition, offered a presentation on disordered eating in this population.
Healio spoke with O’Hara and Chaves to learn more about diagnosing and

VIDEO: Sacituzumab tirumotecan shows consistent survival benefits in EGFR-mutated NSCLC

COPENHAGEN, Denmark — In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses results from the OptiTROP-Lung03 study, which were presented at European Lung Cancer Congress.
The study evaluated sacituzumab tirumotecan (sac-TMT, Merck), a TROP-2 directed antibody-drug conjugate, vs. docetaxel among pretreated patients with EGFR-mutated non-small cell lung cancer.
Results of a final OS analysis favored sac-TMT (median, 20 months vs. 11.2 months).
“This agent is looking really, really nice in the EGFR-mutant space,” Cooper said.

EVT improves symptoms of post-thrombotic syndrome

Endovascular therapy after deep vein thrombosis for patients with post-thrombotic syndrome and iliac vein obstruction improved symptoms and patient-reported quality of life vs. standard care, researchers reported.
Elevated bleeding events after endovascular therapy (EVT) represented a trade-off between stent placement and standard care in patients with post-thrombotic syndrome and iliac vein obstruction, although bleeding severity for the most part was low, according to the results of the phase 3, multicenter, open-label, assessor-masked, randomized controlled C-TRACT trial published in The

Postop hyperopia possible in radial keratotomy eyes

Performing cataract surgery on a patient with a history of radial keratotomy is one of the most challenging scenarios in modern anterior segment surgery.
These patients are often among the most demanding because they sought refractive independence decades ago and now face a complex optical landscape. To achieve a successful outcome, we must navigate the unique corneal biomechanics of the RK eye, specifically focusing on the shift toward hyperopia both preoperatively and in the immediate postoperative period.
RK works by creating deep peripheral incisions, typically exceeding 90% depth, that

Top AAD takeaways from Susan C. Taylor, MD, FAAD

This year’s American Academy of Dermatology Annual Meeting offered networking opportunities, late-breaking clinical research and hundreds of educational sessions, as well as forums supporting women’s leadership and career advancement.
More than 20,000 attendees from all over the world attended this year’s AAD Annual Meeting, according to immediate past president Susan C. Taylor, MD, FAAD The agenda included more than 300 sessions, nearly 2,000 e-posters and more than 400 oral presentations — the most in the history of the meeting, according to Taylor.
“It has truly been an extraordinary year,”

Foundayo confers noninferior heart risk vs. insulin glargine

A once-daily oral GLP-1 was noninferior to insulin glargine for reducing cardiovascular risk among adults with type 2 diabetes and overweight or obesity at high risk for CV events, according to topline results from the ACHIEVE-4 trial.
As Healio previously reported, orforglipron (Foundayo, Eli Lilly) was approved by the FDA on April 1 for the treatment of overweight or obesity. In ACHIEVE-4, researchers compared orforglipron to insulin glargine among 2,749 adults with type 2 diabetes plus overweight or obesity who had increased risk for CV events. All adults took between one and three oral

Multiple sclerosis prevalence rises, mortality falls

Although the prevalence of MS more than doubled in England between 2000 and 2020, survival rates improved, according to a research letter published in JAMA Neurology.
Additionally, the researchers wrote, disparities in mortality have emerged.
“This study was prompted by the steady rise in MS prevalence in England, alongside ongoing uncertainty about how modifiable factors such as smoking, body weight and socioeconomic deprivation affect survival,” Raffaele Palladino, PhD, MD, professor, department of primary care and public health, Imperial College London, and Olga Ciccarelli, PhD, FRCP,

CGM may predict future diabetes risk for youths with prediabetes

Continuous glucose monitoring metrics may be able to predict future glycemic trajectories for children and adolescents with prediabetes, according to study findings published in Diabetes Technology & Therapeutics.
In an analysis of data from 29 youths with prediabetes who wore a CGM, increased time above range with glucose of more than 140 mg/dL was tied to higher HbA1c at 6 months and greater change in HbA1c from baseline to 6 months, despite mean HbA1c remaining relatively stable in the study group, according to Natalie Segev, MD, MS, metabolic research fellow in the division of diabetes

Telehealth use rose for patients with kidney failure after 2020

Both rural and urban Medicare beneficiaries with kidney failure used telehealth services significantly more during the COVID-19 pandemic compared with before, according to study data published in Kidney Medicine.
Telehealth use trends have been explored among various populations since the COVID-19 pandemic, but less is known about telehealth adoption among patients with kidney failure on dialysis, a population that more often needs in-person treatments, according to Joel T. Adler, MD, MPH, assistant professor of surgery and perioperative care in the division of transplant surgery at Dell